Theravance Biopharma (NASDAQ:TBPH) Reaches New 12-Month High - What's Next?

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report)'s stock price reached a new 52-week high on Tuesday . The company traded as high as $11.21 and last traded at $11.15, with a volume of 1805901 shares changing hands. The stock had previously closed at $9.16.

Analyst Ratings Changes

TBPH has been the subject of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Theravance Biopharma presently has a consensus rating of "Hold" and an average price target of $11.33.

Theravance Biopharma Trading Up 4.5%

The firm has a market capitalization of $562.51 million, a price-to-earnings ratio of -11.14 and a beta of -0.10. The firm has a 50 day moving average price of $9.35 and a two-hundred day moving average price of $9.40.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The business had revenue of $15.39 million for the quarter, compared to analyst estimates of $28.08 million. As a group, research analysts forecast that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Insider Activity

In related news, SVP Rhonda Farnum sold 4,000 shares of the company's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 370,038 shares of the company's stock, valued at $3,330,342. This represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On Theravance Biopharma

A number of large investors have recently bought and sold shares of TBPH. Aquatic Capital Management LLC bought a new position in Theravance Biopharma during the 4th quarter worth $25,000. GAMMA Investing LLC boosted its position in Theravance Biopharma by 1,201.8% during the 1st quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 3,281 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Theravance Biopharma in the fourth quarter worth $69,000. AQR Capital Management LLC acquired a new position in shares of Theravance Biopharma during the first quarter valued at $101,000. Finally, Teacher Retirement System of Texas acquired a new stake in Theravance Biopharma in the fourth quarter worth about $103,000. Institutional investors own 99.10% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.